takeda_usa_pharmaceuticals_u

Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

pharmafile | January 30, 2019 | News story | Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases 

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing Phase 3 trial.

The tetravalent vaccine, which was found to be well tolerated, met its primary efficacy endpoint in a pivotal Phase 3 trial.

“We are very encouraged by the performance of our dengue vaccine candidate in the study. This brings us one step closer to helping the world tackle the massive burden of dengue,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda.

Advertisement

“We are excited to publish the data in a peer-reviewed journal as quickly as possible. In parallel, we are advancing the clinical development, commercial manufacturing, and stakeholder consultations to support a potential future global launch of the vaccine.”

The trial enrolled 20,000 healthy children and adolescents between the ages of four and 16, who were living in dengue-endemic areas.

The Japanese firm is also working on vaccines for other highly infectious including Zika, norovirus and polio.   

Louis Goss

Related Content

drug-trials

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON

Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

The Gateway to Local Adoption Series

Latest content